Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jefferies Weighs in On Axovant Sciences Ltd (AXON)

Analysts at Jefferies recently weighed in on Axovant Sciences Ltd (NYSE:AXON), a biotech whose shares have taken off after Dr. David Hung agreed to become the company’s CEO. Traders have been excited over the name due to Hung’s past history at Medivation, a firm Hung founded, led, and helped sell at a substantial premium to Pfizer. Given that Dr. Hung chose Axovant over his many other job offers, many traders think that Axovant’s drugs could be very promising.

Recently, Biren Amin of Jefferies weighed in on the stock after hosting an investor meeting with Dr. David Hung. According to Armin, Dr. Hung is pretty bullish on intepirdine and nelotanserin, both of which could offer substantial opportunity for value creation if study data backs the drugs up. Specifically for intepirdine, Amin thinks Axovant shares could potentially trade for around $80 to $90 per share if the Phase 3 trials show strong improvement in the ADS-cog scale. If the drug shows moderate improvement, Amin thinks Axovant could trade for around $45 to $50. If the data from the trial comes out badly, Axovant shares could decline to the $5 level. Basically, there is still a wide range of outcomes, and Axovant will remain risky/volatile for the foreseeable future. 16.6% of the float is short.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

According to our data, 16 elite funds were long Axovant Sciences Ltd (NYSE:AXON) at the end of December, down 4 funds from the previous quarter.

The Bottom Line

Axovant Sciences Ltd (NYSE:AXON) could go to either $5 or $90 according to recent Jefferies commentary. For more reading, check out ‘11 Cities with Most Doctors Per Capita in America‘.

Follow Axovant Sciences Ltd.
Trade (AXON) Now!

Disclosure:None

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Loading...